Insights into Skeletal Metabolism and Osteoporosis Therapies

OR08-1

Retreatment with Romosozumab after 12 Months of Placebo Demonstrates Similar BMD Efficacy Compared with Initial Romosozumab Treatment
D L Kendler, H G Bone, F Massari, E Gielen, S Palacios, J Maddox, C Yan, C Libanati, S Yue and A Grauer

OR08-2

Transition to Zoledronic Acid after Romosozumab Treatment Maintains Bone Mineral Density Gains
M R McClung, M A Bolognese, J P Brown, J-Y Reginster, B L Langdahl, J Maddox, C Yan, S Yue, P D Meisner and A Grauer

OR08-3

Vertebral Fracture Incidence after Discontinuation of Denosumab Treatment: Analysis from Freedom and Its Extension
Serge Ferrari, Jacques P Brown, Nico Pannacciulli, Nigel Gilchrist, Christian Roux, Ove Törring, Ivo Valter, Rachel B Wagman, Andrea T Wang and Steven R Cummings

OR08-4

The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab: Results from the Freedom and Freedom Extension Studies
David L Kendler, A Chines, M L Brandi, S Papapoulos, E M Lewiecki, J-Y Reginster, C Roux, M Munoz Torres, A Wang and H G Bone

OR08-5

High Turnover Bone Disease Due to a Novel 27-Base Pair Tandem Duplication in TNFRSF11A leading to Constitutively Active RANK
Sean J. Iwamoto, Micol S. Rothman, Shenghui Duan, Steven Mumm, Kelsey Burr and Michael P. Whyte

OR08-6

Lower Bone Formation after 3 Weeks of Sleep Restriction with Circadian Disruption: A Mechanism for Sleep-Related Bone Loss
Christine Swanson, Steven A Shea, Pamela Wolfe, Sheila Markwardt, Charles A Czeisler, Orfeu Marcello Buxton and Eric S Orwoll

OR08-7

Comparison of the Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide-SC Versus Placebo during the ACTIVE Trial
Michael R McClung, Gregory C Williams, Gary Hattersley, Lorraine A Fitzpatrick, Yamei Wang and Paul D Miller